Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Rating of “Hold” from Analysts

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have been given an average recommendation of “Hold” by the nine brokerages that are covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $10.00.

Several research analysts have recently commented on the company. Guggenheim reduced their price target on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Wedbush upgraded Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price target on the stock in a report on Monday, August 12th. Oppenheimer reiterated an “outperform” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a report on Friday, November 15th.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL stock opened at $3.34 on Friday. Zentalis Pharmaceuticals has a fifty-two week low of $2.66 and a fifty-two week high of $18.07. The stock’s fifty day moving average is $3.34 and its two-hundred day moving average is $4.65.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.36. On average, equities analysts predict that Zentalis Pharmaceuticals will post -2.48 earnings per share for the current year.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Barclays PLC grew its position in shares of Zentalis Pharmaceuticals by 18.5% during the third quarter. Barclays PLC now owns 75,395 shares of the company’s stock worth $277,000 after buying an additional 11,748 shares in the last quarter. XTX Topco Ltd grew its position in shares of Zentalis Pharmaceuticals by 8.7% during the third quarter. XTX Topco Ltd now owns 194,062 shares of the company’s stock worth $714,000 after buying an additional 15,597 shares in the last quarter. Quarry LP acquired a new position in shares of Zentalis Pharmaceuticals during the third quarter worth about $55,000. Paloma Partners Management Co acquired a new position in shares of Zentalis Pharmaceuticals during the third quarter worth about $37,000. Finally, Erste Asset Management GmbH acquired a new position in Zentalis Pharmaceuticals in the third quarter valued at approximately $37,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.